Rigel Pharmaceuticals, Inc. (RIGL)
Market Cap | 167.14M |
Revenue (ttm) | 120.35M |
Net Income (ttm) | -19.80M |
Shares Out | 175.41M |
EPS (ttm) | -0.11 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 342,914 |
Open | 0.995 |
Previous Close | 0.983 |
Day's Range | 0.950 - 0.995 |
52-Week Range | 0.710 - 1.770 |
Beta | 1.06 |
Analysts | Buy |
Price Target | 5.81 (+511.32%) |
Earnings Date | May 7, 2024 |
About RIGL
Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1)... [Read more]
Financial Performance
In 2023, RIGL's revenue was $116.88 million, a decrease of -2.79% compared to the previous year's $120.24 million. Losses were -$25.09 million, -57.16% less than in 2022.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for RIGL stock is "Buy." The 12-month stock price forecast is $5.81, which is an increase of 511.32% from the latest price.
News
Rigel Reports First Quarter 2024 Financial Results and Provides Business Update
First quarter 2024 total revenue of $29.5 million, which includes TAVALISSE® net product sales of $21.1 million and REZLIDHIA ® net product sales of $4.9 million Expanded Rigel's portfolio with acqui...
Rigel Announces Conference Call and Webcast to Report First Quarter 2024 Financial Results and Business Update
SOUTH SAN FRANCISCO, Calif. , April 30, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its first quarter 2024 financial results after market close ...
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. , April 10, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to Rigel's Inducement Plan, approv...
Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma
Olutasidenib induced durable composite complete remission in 43.8% of patients relapsed or refractory to prior venetoclax-based regimens Safety was consistent with the overall profile of olutasidenib ...
Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer
SOUTH SAN FRANCISCO, Calif. , March 12, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the appointment of Lisa Rojkjaer, M.D.
Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Fourth quarter 2023 Total Revenue of $35.8 million which includes TAVALISSE® net product sales of $25.7 million and REZLIDHIA ® net product sales of $3.9 million Expanded product portfolio with acquis...
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2023 Financial Results and Business Update
SOUTH SAN FRANCISCO, Calif. , Feb. 27, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its fourth quarter and full year 2023 financial results after...
Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO®
GAVRETO® (pralsetinib) is an FDA approved targeted therapy for the treatment of RET fusion-positive metastatic non-small cell lung cancer and advanced or metastatic thyroid cancer Acquisition of estab...
Rigel Pharmaceuticals Provides Business Update
Preliminary fourth quarter 2023 total revenue of approximately $35.7 million which includes record TAVALISSE® net product sales of $25.7 million and REZLIDHIA® net product sales of $3.9 million Strate...
Rigel Announces Collaboration with CONNECT to Conduct a Phase 2 Trial of Olutasidenib in Glioma
SOUTH SAN FRANCISCO, Calif. , Jan. 4, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced a collaboration with CONNECT, an international collaborative network of pediatric ...
Rigel to Present at the 42nd Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif. , Jan. 3, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and CEO, will present a company overv...
Rigel Pharmaceuticals and MD Anderson Announce Strategic Alliance to Advance REZLIDHIA® (Olutasidenib) in AML and Other Cancers
SOUTH SAN FRANCISCO, Calif. and HOUSTON , Dec. 8, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) and The University of Texas MD Anderson Cancer Center (MD Anderson) today announced a ...
Rigel Reports Third Quarter 2023 Financial Results and Provides Business Update
Third quarter 2023 Total Revenue of $28.1 million which includes record TAVALISSE® net product sales of $24.5 million and REZLIDHIA® net product sales of $2.7 million New data on olutasidenib in mIDH1...
Rigel to Present at the Jefferies London Healthcare Conference
SOUTH SAN FRANCISCO, Calif. , Nov. 6, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Dean Schorno, the company's chief financial officer, will present a company o...
Rigel Announces Poster Presentations at the 65th American Society of Hematology Annual Meeting and Exposition
-- Growing body of data on REZLIDHIA® (olutasidenib) in mIDH1 relapsed or refractory (R/R) acute myeloid leukemia (AML) patients -- -- New data on olutasidenib in patients with mIDH1 myelodysplastic s...
Rigel Announces Conference Call and Webcast to Report Third Quarter 2023 Financial Results and Business Update
SOUTH SAN FRANCISCO, Calif. , Oct. 31, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its third quarter 2023 financial results after market close o...
Rigel Announces Presentation at the Upcoming IDWeek 2023
-- Provides Update on ACTIV-4 Host Tissue Trial -- SOUTH SAN FRANCISCO, Calif. , Oct. 11, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced an upcoming oral presentation ...
Rigel to Present at the 2023 Cantor Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif. , Sept. 20, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Dean Schorno, the company's chief financial officer, will present a company...
Rigel to Participate in Upcoming September Investor Conferences
SOUTH SAN FRANCISCO, Calif. , Aug. 30, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, and Dea...
Rigel Reports Second Quarter 2023 Financial Results and Provides Business Update
Second quarter 2023 Total Revenue of $26.9 million which includes TAVALISSE® net product sales of $21.3 million and REZLIDHIA® net product sales of $2.6 million Development programs continue to advanc...
Rigel Announces Conference Call and Webcast to Report Second Quarter 2023 Financial Results and Business Update
SOUTH SAN FRANCISCO, Calif. , July 25, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its second quarter 2023 financial results after market close ...
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. , July 5, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. I...
Rigel Announces Presentation of Data from Analysis of REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML
Durable remissions observed in patients relapsed or refractory to prior venetoclax-based regimens Data featured in a poster presentation at the European Hematology Association (EHA) 2023 Hybrid Congre...
Rigel Announces Second REZLIDHIA® (Olutasidenib) Publication in Blood Advances
Review article examines the preclinical and clinical development, and the role of olutasidenib in the mIDH1 AML treatment landscape. Authors conclude, "The approval of olutasidenib is a critical addit...
Rigel Announces Poster Presentation at the Upcoming 2023 American Society of Clinical Oncology Annual Meeting
SOUTH SAN FRANCISCO, Calif. , June 1, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced an upcoming poster presentation highlighting the Company's IRAK1/4 program at the ...